PureTech Health lowers stake in founded entity
PureTech Health
154.80p
12:40 24/12/24
-1.02%
-1.60p
Clinical stage biotechnology company PureTech Health said on Tuesday that it had received $45m from the sale of 555,500 shares of its founded entity Karuna Therapeutics.
FTSE 250
20,571.51
13:00 24/12/24
n/a
n/a
FTSE 350
4,491.87
12:54 24/12/24
n/a
n/a
FTSE All-Share
4,449.61
13:14 24/12/24
n/a
n/a
Pharmaceuticals & Biotechnology
20,055.90
12:54 24/12/24
0.25%
50.73
Following the transaction, PureTech will continue to hold 4.73m shares in Karuna, equal to 18.1% of the group, and has a right to royalty payments on net sales of any commercialised product covered by a license granted by PureTech to Karuna.
The FTSE 250-listed group intends to use the proceeds from the transaction to fund its growth potential.
PureTech has generated over $255m in the past six months from the combined sales of minority portions of founded entity shares.
As of 0850 BST, PureTech shares were up 1.42% at 252.03p.